Effects of Early-Adolescent, Mid-Adolescent, or Adult Stress on Morphine Conditioned Place Preference

In light of previous work demonstrating that stress can increase subjective drug reward in adult rats, the present study investigated the influence of stress on morphine conditioned place preference (CPP) in early-adolescent, mid-adolescent, and adult male Sprague-Dawley rats. Subjects in each age group were assigned to either a no stress condition or a stress condition in which they were exposed to an unpredictable eight-day schedule of elevated platform and synthetic fox odor stressors. Place conditioning then evaluated subjective morphine reward in all animals. Using a biased procedure, subjects were assigned to receive morphine on the initially non-preferred side of the apparatus and saline on the initially preferred side as identified at pretest. After eight days of conditioning in which drug presentation alternated by day (i.e., morphine one day and saline the next), a post-test was conducted identical to pre-test. Results comparing pre- and post-test time on the non-preferred side indicated no difference between stress conditions or age groups, though place preference was observed in all animals. Activity, scored as midline crosses during conditioning trials, revealed expected habituation to the motor suppressing effects of morphine. Although no effects of stress or age were observed on measures of drug conditioning, the findings suggest that duration between the end of stress exposure and the start of conditioning may have weakened any effect of age-dependent stress on morphine CPP

Refracting the Male Gaze: Mary Cassatt’s Ocularcentric Message of Female Agency

Through analysis of ocularcentric (vision-privileged) messages in Mary Cassatt’s Reading Le Figaro (1878), I argue the portrait represents a strong early-career interest in countering gender hegemony that is largely unmatched in the artist’s later work. Reading the painting as a reaction to decreased autonomy following a consolidation of family living spaces, the present paper satisfies a dearth in Cassatt scholarship by addressing a yet-undiscussed motif of vision in Cassatt’s painting: the mirror. In a complete subversion of classic vanitas paintings, Cassatt alters the woman-and-mirror trope to emphasize her subject’s desire for an identity of female mind over female body. Defying European culture’s hyperspecularization (concentration on display value), which converted women into objects of male desire, Reading Le Figaro challenges preconceived schemas of gender and offers autonomy, self-definition, and active female sight as alternatives to the gaze-controlling subjugation of women

Person to Person in Ecuador

While still in the midst of their study abroad experiences, students at Linfield College write reflective essays. Their essays address issues of cultural similarity and difference, compare lifestyles, mores, norms, and habits between their host countries and home, and examine changes in perceptions about their host countries and the United States. In this essay, Chloe Shield describes her observations during her study abroad program at the Universidad San Francisco de Quito in Ecuador

Effects of Early-Adolescent, Mid-Adolescent, or Adult Stress on Morphine Conditioned Place Preference

Early-life stress is correlated with negative mental health outcomes, including illicit drug abuse. One mechanism that may contribute to drug abuse is stress-induced elevation of drug reward. Place conditioning paradigms show that exposure to uncontrollable stress as an adult enhances opiate conditioned place preference, CPP. The present work addressed whether early-adolescent, mid-adolescent, or adult stress amplified morphine CPP. Male Sprague-Dawley rats were randomly assigned to stress or no stress conditions and received stress during early-, mid-adolescence, or adulthood. Stressors were unpredictable consisting of exposure to synthetic fox odor (trimethylthiazoline) and an elevated platform. Morphine place conditioning occurred during adulthood, and all animals received either morphine (15 mg/kg) on the initially non-preferred side or saline (1 ml/kg) on the initially preferred side. A post-test was conducted and time on non-preferred side was analyzed. A 2 (S/NS) x 2 (pre-/post-test) x 3 (early-adolescent/mid-adolescent/adult) mixed ANOVA revealed a significant main effect of test, F(1,42)=115.90, p \u3c .001

Reducing Stigma toward the Transgender Community: An Evaluation of a Humanizing and Perspective-Taking Intervention

Transgender (TG) individuals are an understudied group at high risk of experiencing discrimination and associated adverse mental health outcomes (IOM, 2011). Although many studies demonstrate that contact reduces negative attitudes toward out-groups, few studies have examined the link between contact and attitudes toward the TG community (Hill & Willoughby, 2005; Walchet al., 2012). This study represents one of the first attempts to understand how to effectively reduce stigma toward the TG community. Results indicate that education alone is not enough to change attitudes; in fact, there is some evidence that associating transgenderism with psychopathology may heighten stigma. Consistent with prior research on stigma towards the mentally ill, the current study suggests that both exposure to intimate media depictions of the “other” (Reinke et al., 2004) and perspective-taking (Mann & Himelein, 2008) could strengthen educational campaigns designed to combat stigma

SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study

BACKGROUND: Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood. OBJECTIVES: COVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination. METHODS: Individuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs. RESULTS: A total of 5.6% (n = 320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n = 168) compared with 100% of healthy controls (n = 205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p = 0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p = 0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine. CONCLUSION: SARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection

Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study

Background Although a preventable and treatable disease, tuberculosis causes more than a million deaths each year. As countries work towards achieving the Sustainable Development Goal (SDG) target to end the tuberculosis epidemic by 2030, robust assessments of the levels and trends of the burden of tuberculosis are crucial to inform policy and programme decision making. We assessed the levels and trends in the fatal and non-fatal burden of tuberculosis by drug resistance and HIV status for 195 countries and territories from 1990 to 2016. Methods We analysed 15 943 site-years of vital registration data, 1710 site-years of verbal autopsy data, 764 site-years of sample-based vital registration data, and 361 site-years of mortality surveillance data to estimate mortality due to tuberculosis using the Cause of Death Ensemble model. We analysed all available data sources, including annual case notifications, prevalence surveys, population-based tuberculin surveys, and estimated tuberculosis cause-specific mortality to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a Bayesian meta-regression tool. We assessed how the burden of tuberculosis differed from the burden predicted by the Socio-demographic Index (SDI), a composite indicator of income per capita, average years of schooling, and total fertility rate. Findings Globally in 2016, among HIV-negative individuals, the number of incident cases of tuberculosis was 9·02 million (95% uncertainty interval [UI] 8·05–10·16) and the number of tuberculosis deaths was 1·21 million (1·16–1·27). Among HIV-positive individuals, the number of incident cases was 1·40 million (1·01–1·89) and the number of tuberculosis deaths was 0·24 million (0·16–0·31). Globally, among HIV-negative individuals the age-standardised incidence of tuberculosis decreased annually at a slower rate (–1·3% [–1·5 to −1·2]) than mortality did (–4·5% [–5·0 to −4·1]) from 2006 to 2016. Among HIV-positive individuals during the same period, the rate of change in annualised age-standardised incidence was −4·0% (–4·5 to −3·7) and mortality was −8·9% (–9·5 to −8·4). Several regions had higher rates of age-standardised incidence and mortality than expected on the basis of their SDI levels in 2016. For drug-susceptible tuberculosis, the highest observed-to-expected ratios were in southern sub-Saharan Africa (13·7 for incidence and 14·9 for mortality), and the lowest ratios were in high-income North America (0·4 for incidence) and Oceania (0·3 for mortality). For multidrug-resistant tuberculosis, eastern Europe had the highest observed-to-expected ratios (67·3 for incidence and 73·0 for mortality), and high-income North America had the lowest ratios (0·4 for incidence and 0·5 for mortality). Interpretation If current trends in tuberculosis incidence continue, few countries are likely to meet the SDG target to end the tuberculosis epidemic by 2030. Progress needs to be accelerated by improving the quality of and access to tuberculosis diagnosis and care, by developing new tools, scaling up interventions to prevent risk factors for tuberculosis, and integrating control programmes for tuberculosis and HIV

Mapping 123 million neonatal, infant and child deaths between 2000 and 2017

Since 2000, many countries have achieved considerable success in improving child survival, but localized progress remains unclear. To inform efforts towards United Nations Sustainable Development Goal 3.2—to end preventable child deaths by 2030—we need consistently estimated data at the subnational level regarding child mortality rates and trends. Here we quantified, for the period 2000–2017, the subnational variation in mortality rates and number of deaths of neonates, infants and children under 5 years of age within 99 low- and middle-income countries using a geostatistical survival model. We estimated that 32% of children under 5 in these countries lived in districts that had attained rates of 25 or fewer child deaths per 1,000 live births by 2017, and that 58% of child deaths between 2000 and 2017 in these countries could have been averted in the absence of geographical inequality. This study enables the identification of high-mortality clusters, patterns of progress and geographical inequalities to inform appropriate investments and implementations that will help to improve the health of all populations

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

As mortality rates decline, life expectancy increases, and populations age, non-fatal outcomes of diseases and injuries are becoming a larger component of the global burden of disease. The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016